U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800429) titled 'Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib' on Aug. 28.
Brief Summary: The primary objective of this trial is to assess the effect of a known P-gp inhibitor, itraconazole, on the PK of engasertib in healthy adult participants.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Engasertib
Participants will take engasertib orally as capsules.
DRUG: Itraconazole
Participants will take itraconazole as 20 mL of 10 mg/mL oral solution.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vaderis Therapeutics AG...